Bio-Thera Reported Positive Results of BAT2206 (biosimilar ustekinumab) in P-III Study for Patients with Plaque Psoriasis
- The P-III (NCT04728360) study evaluating safety, efficacy, immunogenicity & PK of BAT2206 with Stelara in patients (n=556) with moderate to severe plaque psoriasis.
- The 1EP of the study was to evaluate the improvement in the Psoriasis Area & Severity Index (PASI) score from the baseline to Week 12. The results of the study will be presented at future medical meetings & Publication
- BAT2206, a potential biosimilar of Janssen's Stelara is human mAb that suppresses the bioactivity of human IL-12 and IL-23 by inhibiting shared p40 from binding to the IL-12Rβ1 receptor protein found on the surface of immune cells
Ref: Bio-Thera Solutions | Image: Bio-Thera Solutions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at firstname.lastname@example.org.